Gilead, Pharmacyclics to Benefit?
Higher Death Rate Prompts Halt in Revlimid CLL Trial
By Jennifer Boggs
Friday, July 19, 2013
Analysts remained relatively unconcerned following Celgene Corp.'s news that it halted a Phase III study testing Revlimid (lenalidomide) in front-line elderly B-cell chronic lymphocytic leukemia (CLL) due to an imbalance in the number of deaths between the Revlimid and control arms, though up and coming competitors could benefit from the minor setback.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.